<DOC>
	<DOC>NCT00141518</DOC>
	<brief_summary>The primary objective of this study is to collect health economic data depicting the initial levels and natural progression over time of resource usage, Parkinson's disease (PD)-related costs, and health related quality of life (HRQoL) for a cohort of advanced PD patients treated with Duodopa (levodopa-carbidopa in an intestinal gel formulation), of which about one-third were Duodopa-na√Øve prior to the start of the study.</brief_summary>
	<brief_title>Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes &amp; Net Economic Impact</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa, levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Advanced idiopathic Parkinson's disease Other diseases which might influence compliance or participation in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Health economics,Quality of life</keyword>
</DOC>